CN103735643B - 治疗糖尿病周围神经病变的中药组合物 - Google Patents
治疗糖尿病周围神经病变的中药组合物 Download PDFInfo
- Publication number
- CN103735643B CN103735643B CN201410025537.3A CN201410025537A CN103735643B CN 103735643 B CN103735643 B CN 103735643B CN 201410025537 A CN201410025537 A CN 201410025537A CN 103735643 B CN103735643 B CN 103735643B
- Authority
- CN
- China
- Prior art keywords
- treatment
- chinese medicine
- medicine composition
- parched
- peripheral neuropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 75
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 208000032131 Diabetic Neuropathies Diseases 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 241000208340 Araliaceae Species 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims description 18
- 239000006187 pill Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 210000000952 spleen Anatomy 0.000 abstract description 16
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 238000010792 warming Methods 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 206010003246 arthritis Diseases 0.000 abstract description 6
- 230000008506 pathogenesis Effects 0.000 abstract description 6
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 208000032023 Signs and Symptoms Diseases 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 210000003414 extremity Anatomy 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 230000035922 thirst Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 231100000862 numbness Toxicity 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010002027 Amyotrophy Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000004345 peroneal nerve Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 210000001590 sural nerve Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- ZFLASALABLFSNM-QBOHGLHMSA-L carbanide;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-oc Chemical compound [CH3-].[Co+3].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ZFLASALABLFSNM-QBOHGLHMSA-L 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108010065691 Biphasic Insulins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000189 biphasic insulin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000006994 chronic ulcer of skin Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000020880 diabetic diet Nutrition 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 229940103453 novolin Drugs 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 230000036616 oligospermia Effects 0.000 description 1
- 231100000528 oligospermia Toxicity 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000037118 sensory ataxia Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000008423 tao-shang-tsao Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108010080213 vascular factor Proteins 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗糖尿病周围神经病变的中药组合物,属于中医药领域,包括以下重量数的组分:炙淫羊藿8-12g、桂枝6-12g、人参4-8g、麸炒白术8-12g、茯苓8-12g、炒白芍7-12g和川芎7-11g。本中药组合物在中医理论的指导下,辨证论治,理法兼备,配伍科学,具有温补脾肾、祛湿通络之功效,且量小力专,见效快,药效显著,安全性好,无明显不良反应及毒副作用,使用方便,经济成本低,有利于临床推广应用。
Description
技术领域
本发明属于中医药领域,具体涉及一种治疗糖尿病周围神经病变的中药组合物。
背景技术
糖尿病周围神经病变(DiabeticPeripheralNeuropathy,DPN)是指在排除其他原因的情况下,糖尿病患者出现与周围神经功能障碍相关的症状和(或)体征,其中2型糖尿病神经病变发病率高达61.8%。主要表现为:四肢对称性疼痛、麻木、感觉异常、肌肉萎缩,可引起感觉性共济失调,并可因反复轻微外伤、感染和供血不足而发生无痛性溃疡和神经源性骨关节病,是糖尿病致残的重要原因之一。
目前,DPN发病机制尚未完全明了,主要涉及多元醇通路激活、非酶蛋白糖基化作用、氧化应激、血管因素、神经生长因子的缺失等,临床上没有明确(特效)治疗糖尿病周围神经病变的药物。西医多采用控制血糖、营养神经、改善微循环,抗氧化应激、及对症治疗等方法治疗,主要药物有甲钴铵,α-硫辛酸,前列腺素E2、依帕司他、神经营养因子、卡马西平、阿米替林等,这些药物针对DPN的不同发病机理均能起到一定的治疗作用,但对于病程长、病情重的疑难病例,疗效不理想,部分药物价格昂贵,临床难以推广应用。
中医学认为糖尿病属“消渴”病范畴,糖尿病周围神经病变,多以“消渴肢痹”论治,主要由消渴病日久失治误治发展而成,消渴病的病因病机主要由五脏皆柔弱、功能失常、饮食不节、情志失调等导致阴虚内热,渐致气阴两虚、阴阳两虚,消渴日久变证丛生,当经脉失养,络脉痹阻即发为“消渴肢痹”,其主要病机为气血阴阳亏虚为本,湿浊内停、络脉瘀滞为标,属消渴病后期虚实夹杂的疑难病症之一。
近年来,运用中医药治疗糖尿病周围神经病变取得一定进展,多采用益气养阴、活血化淤的治疗方法,例1:刘杰的发明“一种治疗糖尿病性神经病变的中药”(专利号为:01117630.X),功能为:益气养血、缓急止痛、舒筋活血;例2:木丹颗粒,功效为益气活血,通络止痛,主治糖尿病性周围神经病变属气虚络阻证,但对于DPN属脾肾阳虚、湿瘀阻络证病人疗效不理想。
DPN脾肾阳虚、湿瘀阻络证临床表现为肢体及躯干麻木、刺痛、无力,或见畏寒肢冷、下肢发凉、浮肿、腰膝酸软、阳痿、自汗、胫前瘀斑,重者可见下肢关节病及溃疡、肌萎缩等,目前市场上尚无针对性治疗药物。
发明内容
本发明针对现有技术的不足,提供了一种具有温补脾肾、祛湿通络之功效,且见效快、药效显著、价格低廉、使用方便的治疗糖尿病周围神经病变的中药组合物。
为了实现上述发明目的,本发明采用的技术方案为:
本发明所述的治疗糖尿病周围神经病变的中药组合物,包括以下重量数的组分:炙淫羊藿8-12g、桂枝6-12g、人参4-8g、麸炒白术8-12g、茯苓8-12g、炒白芍7-12g和川芎7-11g。
所述的治疗糖尿病周围神经病变的中药组合物,包括以下重量数的组分:炙淫羊藿9-11g、桂枝8-10g、人参5-7g、麸炒白术9-11g、茯苓9-11g、炒白芍8-10g和川芎8-10g。
所述的治疗糖尿病周围神经病变的中药组合物,包括以下重量数的组分:炙淫羊藿10g、桂枝9g、人参6g、麸炒白术12g、茯苓10g、炒白芍9g和川芎9g。
所述中药组合物为水泛丸、滴丸、颗粒剂、片剂、胶囊剂或者口服液中的任意一种。
方中炙淫羊藿辛、甘、温,归肝肾经,功能为补肾阳、强筋骨、祛风湿,善治肾阳虚衰、肢体麻木、风湿痹痛、筋骨痿软、阳痿遗精,为君药;桂枝性味辛、甘、温,归心、肺、膀胱经,功能为发汗解肌,温通经脉,助阳化气,平冲降气,主治血寒经闭,关节痹痛,痰饮,水肿等,善温通心阳,助炙淫羊藿温补肾阳,为臣药;人参甘、微苦、微温,归脾、肺、心、肾经,功能为大补元气,补脾益肺,生津养血,用于久病虚赢、内热消渴、气血亏虚、肢冷脉微、阳痿宫冷等,《金匮要略》记载“渴欲饮水,口干舌燥者,白虎加人参汤主之”,为治疗消渴之要药,桂枝与人参合用补心气,助心阳,为臣药;白术苦、甘、温,归脾、胃经,功能为健脾益气、燥湿利水、止汗,善治脾虚食少、痰饮水肿、自汗等,白术与人参合用健脾燥湿复脾阳,为臣药;茯苓甘、淡、平,归心、肺、脾、肾经,功能为利水渗湿、健脾宁心,主治水肿尿少、痰饮、脾虚食少、心神不安,可助白术祛湿,为佐药;炒白芍苦、酸、微寒,归肝、脾经,功能为养血调经、敛阴止汗、柔肝止痛,用于四肢挛痛,胁痛,腹痛,自汗,盗汗等,《本经》记载芍药“能利小便”有助治疗水肿,配桂枝可调和营卫,其性阴敛可防炙淫羊藿、白术等温燥之品伤阴之弊,为佐药;川芎辛、温,归肝、胆、心包经,功能活血行气、通络止痛,主治胸胁刺痛、肢体痹痛等,辛香走串,为血中气药,可引药入络,直达病所,为使药。全方共奏温补脾肾、祛湿通络之效,使四肢肌肉、筋脉、经络得阳气温养,湿瘀无留滞之所、血脉通利,则肢体麻木、疼痛、乏力等诸症消失。
与现有技术相比,本发明的优点在于:本方在中医理论的指导下,辨证论治,理法兼备,配伍科学,具有温补脾肾、祛湿通络之功效,且量小力专,见效快,药效显著,安全性较好,无明显不良反应及毒副作用,使用方便,经济成本较低,有利于临床推广应用。
具体实施方式
实施例1
治疗糖尿病周围神经病变的中药组合物,包括以下重量数的组分:
实施例2
治疗糖尿病周围神经病变的中药组合物,包括以下重量数的组分:
实施例3
治疗糖尿病周围神经病变的中药组合物,包括以下重量数的组分:
以上药物均为中药饮片,其质量均符合《中国药典》2010年版(一部)各品种项下质量要求,以上药材,灭菌、烘干、粉碎、过100目筛、混合,按泛制法制成水丸,60℃干燥48小时,分装即得,将干燥好的水丸分装于固体药用高密度聚乙烯瓶中,每瓶54克。
本剂型系中药传统剂型---丸剂(水丸),配方药物精少,确保单味中药有效治疗剂量的摄入,口服后在体内溶散、吸收,且不含其他固体赋形剂,实际含药量高,能充分发挥中药的效能,作用持久,适用于慢性病的治疗。
临床资料
观察病例为2011年8月至2013年8月在济宁市中医院糖尿病科(山东省重点中医专科)就诊人群,筛选符合糖尿病周围神经病变(DPN)属脾肾阳虚、湿瘀阻络证患者316例,随机分为甲、乙两组,两组均给予基础治疗:
基础治疗:按照中华医学会糖尿病分会编写的《中国2型糖尿病治疗指南》(2010年版)制定糖尿病饮食、合理运动,糖尿病教育,血糖监测方案,由糖尿病教育专员负责落实以上方案,治疗目标为2型糖尿病综合控制目标,稳定血糖选用:精蛋白生物合成预混人胰岛素(诺和灵)30R于每日早、晚餐前30分钟皮下注射、盐酸二甲双胍(格华止)0.5-1.5/日(根据血糖水平调整药物剂量)营养神经:甲钴胺片(弥可保)500ug/片,每日3次。
甲组为对照组:给予基础治疗,疗程12周。
乙组为治疗组:给予基础治疗,在基础治疗的基础上,服用实施例3制备的中药组合物丸剂,9g/次,每日2次。分别于早、晚餐后60分钟温开水送服,疗程12周。
医嘱:服药期间禁食生凉、油腻、辛辣刺激之品。
研究结果如下:
(一)一般临床资料观察
本研究共纳入病历316例,其中治疗组及对照组各158例,两组之间在性别、年龄、体重指数、糖尿病病程及DPN病程上无统计学意义(P均>0.05),说明两组之间具有可比性。(见表1)
表1治疗组及对照组治疗一般临床资料比较
(二)治疗前后中医症状积分比较
1.两组治疗前后中医证候总积分比较
两组治疗前后中医证候总积分比较:两组治疗前中医证候总积分无差异(P>0.05)。两组治疗后中医证候总积分,均较治疗前明显降低,有显著差异。治疗后中医证候总积分比较,治疗组优于对照组,两组间有显著差异(P<0.01)(见表2)
表2.两组治疗前后中医证候总积分比较
2.两组治疗后中医证候综合疗效比较
治疗组优于对照组,两组间有显著差异(P<0.01)。(见表3)
表3两组治疗后中医症候综合疗效比较
(三)多伦多评分标准(TCSS)疗效比较
治疗前两组间无统计学差异(P>0.05),治疗后均较治疗前明显降低,有显著差异。治疗后TCSS积分比较,治疗组优于对照组,两组间有显著差异(P<0.01)(见表4)
表4两组间治疗前后TCSS疗效比较
(四)两组患者治疗前后腓总神经运动传导速度比较
治疗组与对照组比较疗前无显著差异(P>0.05)。两组治疗前后腓总神经运动传导速度均有提高,其中治疗组与治疗前比较有显著差异(P<0.01),两组治疗后比较治疗组优于对照组,两组间有差异(P<0.05)。(见表5)
表5.两组患者治疗前后腓总神经运动传导速度比较
(五)两组患者治疗前后腓肠神经感觉传导速度比较
治疗组与对照组比较疗前无显著差异(P>0.05)。两组治疗前后腓肠神经感觉传导速度均有提高,但无显著差异(P>0.05),两组治疗后比较无显著差异(P>0.05)。见表6。
表6两组患者治疗前后腓肠神经感觉传导速度比较
(六)两组患者治疗前后糖化血红蛋白和空腹血糖水平比较
治疗组与对照组比较疗前无差异(P>0.05),两组治疗前后无差异(P>0.05),两组治疗后组间比较无差异(P>0.05)。(见表7)
表7两组患者治疗前后糖化血红蛋白和空腹血糖水平比较
(七)安全性评价结果:
整个研究过程中,血压、血、尿、大便常规、肝功能(ALT、AST)、肾功能(BUN、Cr)和心电图正常等安全性指标未出现异常。无药物不良反应发生,病例无1例脱落。
上述病例研究结果显示:本发明所述的治疗糖尿病周围神经病变的中药组合物能够降低DPN患者症候积分,尤其明显的改善肢体麻木、刺痛、乏力等的临床症状,能明显降低TCSS评分、能通过纠正脾肾阳虚、湿瘀阻络状态,改善神经功能。说明在西药常规治疗的基础上,加用本发明所述的治疗糖尿病周围神经病变的中药组合物,能够从以上多方面多环节对DPN起到防治作用,疗效确切,且安全性较好,无明显不良反应及毒副作用,具有临床应用价值。
通过长期临床观察发现:DPN患者后期多见肢体及躯干麻木、刺痛、无力,或见畏寒肢冷、下肢发凉、浮肿、腰膝酸软、阳痿、自汗、胫前瘀斑,重者可见下肢关节病及溃疡、肌萎缩,舌淡(暗)苔白滑、脉沉无力等脾肾阳虚、湿瘀阻络表现,特别近年来由于生物合成人胰岛素的广泛应用,当DPN患者的血糖控制达标后,在中医症候方面,病人“三多一少”等阴虚内热为主的相关症状可以纠正,而胰岛素钠水储留的作用可不同程度加重水湿停滞,使病人阳虚湿盛的表现更为突出,故提出脾肾阳虚、湿瘀阻络是导致DPN发生的重要病机,温阳散寒、祛湿通络是“消渴痹症”的重要治法之一,该方由淫羊藿、桂枝、人参、(麸炒)白术、茯苓、白芍、川芎组成,具有温补脾肾、祛湿通络之效,使四肢肌肉、筋脉、经络得阳气温养,湿瘀无留滞之所、血脉通利,则肢体麻木、疼痛、乏力等诸症消失。
本观察表明,在西医降糖、营养神经等治疗基础上,加用实施例3制备的中药组合物丸剂治疗,在中医证候、TCSS评分、肌电图方面的改善明显优于单纯西医治疗,两组患者治疗前后糖化血红蛋白和空腹血糖水平比较无差异,表明该中药组合物有利于糖尿病患者血糖稳定。安全性指标在治疗前后均无异常,表明本药物安全性高。本方法取材方便、经济成本低廉,适合慢性病患者长期用药,为广大糖尿病患者提供新的治疗途径,对我国人民群众的健康和经济社会的发展都具有重大的现实意义。
Claims (3)
1.一种治疗糖尿病周围神经病变的中药组合物,其特征在于,原料药由以下重量数的组分组成:炙淫羊藿8-12g、桂枝6-12g、人参4-8g、麸炒白术8-12g、茯苓8-12g、炒白芍7-12g和川芎7-11g;该中药组合物为水泛丸、滴丸、颗粒剂、片剂、胶囊剂或者口服液中的任意一种。
2.根据权利要求1所述的治疗糖尿病周围神经病变的中药组合物,其特征在于,原料药由以下重量数的组分组成:炙淫羊藿9-11g、桂枝8-10g、人参5-7g、麸炒白术9-11g、茯苓9-11g、炒白芍8-10g和川芎8-10g。
3.根据权利要求1所述的治疗糖尿病周围神经病变的中药组合物,其特征在于,原料药由以下重量数的组分组成:炙淫羊藿10g、桂枝9g、人参6g、麸炒白术12g、茯苓10g、炒白芍9g和川芎9g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410025537.3A CN103735643B (zh) | 2014-01-20 | 2014-01-20 | 治疗糖尿病周围神经病变的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410025537.3A CN103735643B (zh) | 2014-01-20 | 2014-01-20 | 治疗糖尿病周围神经病变的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103735643A CN103735643A (zh) | 2014-04-23 |
CN103735643B true CN103735643B (zh) | 2015-09-02 |
Family
ID=50492758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410025537.3A Expired - Fee Related CN103735643B (zh) | 2014-01-20 | 2014-01-20 | 治疗糖尿病周围神经病变的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103735643B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104825525B (zh) * | 2015-05-19 | 2018-09-28 | 上海中医药大学 | 一种治疗肌萎缩侧索硬化症的中药组合物及其制备方法 |
CN116139198B (zh) * | 2021-11-22 | 2023-11-28 | 中国中医科学院广安门医院 | 一种治疗糖尿病周围神经病变的中药组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1281716A (zh) * | 1999-07-23 | 2001-01-31 | 王钢柱 | 一种治疗糖尿病周围神经病变的药物 |
CN1600351A (zh) * | 2003-09-23 | 2005-03-30 | 上海方心科技研究所 | 一种用于治疗糖尿病周围神经病变的药物 |
CN102397399A (zh) * | 2010-09-07 | 2012-04-04 | 山东步长制药有限公司 | 一种中药组合物在制备防治糖尿病并发症药物中的应用 |
-
2014
- 2014-01-20 CN CN201410025537.3A patent/CN103735643B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1281716A (zh) * | 1999-07-23 | 2001-01-31 | 王钢柱 | 一种治疗糖尿病周围神经病变的药物 |
CN1600351A (zh) * | 2003-09-23 | 2005-03-30 | 上海方心科技研究所 | 一种用于治疗糖尿病周围神经病变的药物 |
CN102397399A (zh) * | 2010-09-07 | 2012-04-04 | 山东步长制药有限公司 | 一种中药组合物在制备防治糖尿病并发症药物中的应用 |
Non-Patent Citations (1)
Title |
---|
参芎注射液合黄芪桂枝五物汤治疗糖尿病周围神经病变48例;林朝海;《湖南中医杂志》;20090531;第25卷(第3期);第77-78页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103735643A (zh) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102198262A (zh) | 一种治疗小儿轮状病毒性肠炎的中药制剂及其制备方法 | |
CN1247231C (zh) | 一种产后补血保健药物及其制备方法和应用 | |
CN109453460A (zh) | 药石热敷灸基质、含有其的中药组合物及制备方法 | |
CN103735643B (zh) | 治疗糖尿病周围神经病变的中药组合物 | |
CN107496585A (zh) | 一种具有温肾壮阳、补中健脾作用的足浴药包 | |
CN102078586A (zh) | 一种治疗颈椎病的药剂 | |
CN104548049A (zh) | 一种治疗老年性骨质疏松症的中药组合物及其制备方法 | |
CN104225221A (zh) | 一种治疗糖尿病周围性神经病变的中药 | |
CN102000238A (zh) | 九龙胶囊及制备方法 | |
CN107320698A (zh) | 一种治疗中老年神经根型颈椎病的中药复方及其应用 | |
CN106072556A (zh) | 用于调节血糖的保健食品及其制备方法 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN105477180A (zh) | 一种治疗慢性疲劳综合征的中药组合物 | |
CN104225387A (zh) | 一种治疗湿热阻滞型糖尿病足的中药组合物 | |
CN110393796A (zh) | 一种治疗骨关节疼痛的外用膏药及其制备方法 | |
CN104689288B (zh) | 一种治疗慢性低血压的中药制剂 | |
CN114272329B (zh) | 一种治疗肝肾不足型颈椎病的中药组合物、制剂与应用 | |
CN103690771B (zh) | 用于治疗羔羊大肠杆菌病的药物及其制备方法 | |
CN117414351B (zh) | 用于治疗脾肾阳虚便秘的中药贴剂及其制备方法和应用 | |
CN107753921A (zh) | 一种治疗妊娠剧吐的中药贴脐剂 | |
CN107137591A (zh) | 一种治疗痿病的中药组合物 | |
CN105477067A (zh) | 一种治疗湿困脾胃型小儿黄疸的中药组合物 | |
CN106267086A (zh) | 一种治疗原发性青光眼的中药制剂 | |
CN106138246A (zh) | 一种治疗骨折后关节僵硬的中药制剂 | |
CN1895503A (zh) | 一种鹿茸胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150902 |
|
CF01 | Termination of patent right due to non-payment of annual fee |